Previous studies have reported higher GGH expression levels in urothelial, invasive breast, ERG-negative prostate, gallbladder, and gastric cancers compared to corresponding control tissues (Pollard et al., 2009; Silva et al., 2013; Wang et al., 2014; Zali et al., 2019; Muralidharan et al., 2020), which is consistent with our pancancer analysis of TCGA data showing higher GGH expression in numerous cancers including other gynecologic cancers. This evidence concerns the gene ERG and cancer.